Fiche M, Avet-Loiseau H, Heymann M F, Moussaly F, Digabel C, Joubert M, Classe J M, Dravet F, Fumoleau P, Ross J, Maugard C M
University Hospital, Nantes, France.
Int J Cancer. 1999 Oct 22;84(5):511-5. doi: 10.1002/(sici)1097-0215(19991022)84:5<511::aid-ijc11>3.0.co;2-5.
p53 tumor-suppressor gene mutation and p53 protein over-expression have been reported with higher frequency in early-onset breast carcinomas (EOBC). Given the role attributed to normal p53 protein in DNA-repair mechanisms, other somatic genomic alterations would be expected to be associated with this abnormality. Amplification of the c-erbB-2 (HER-2/neu) oncogene and over-expression of the corresponding p185erbB-2 protein have been linked to prognosis and response to therapy in breast cancer. In a retrospective study of 62 formalin-fixed paraffin-embedded invasive EOBC (diagnosed at 35 years or less), the amplification status of the c-erbB-2 gene detected by fluorescence in situ hybridization (FISH) using a unique sequence probe was compared with p53 protein accumulation measured by immunohistochemistry (IHC) and phenotypic features. p185erbB2-protein expression was also detected by immunohistochemistry, together with estrogen-receptor (ER) and progesterone-receptor (PR) expression. The data for a sub-set of 33 node-negative EOBC cases were compared with 70 node-negative tumors diagnosed in women above 36 years of age. Compared with node-negative BC in older women, node-negative EOBC was significantly more likely to feature high grade, high proliferation rate, negative ER and/or PR and p53 over-expression (p < 0.05). A trend toward a higher incidence of c-erbB-2 amplification in EOBC (21% vs. 9%) reached near-significance (p = 0.07). In EOBC, c-erbB-2 amplification and p53 over-expression were not associated with high tumor grade or high cell-proliferation rate, in contrast to the significant associations of these markers in tumors in older women. Abnormalities in tumor markers, including c-erbB-2 gene amplification and p53-protein over-expression, occur at different rates in women with EOBC as compared with BC developing in older women. This finding may reflect a different pathogenesis for EOBC, and warrants further investigation.
据报道,p53肿瘤抑制基因突变和p53蛋白过表达在早发性乳腺癌(EOBC)中出现的频率更高。鉴于正常p53蛋白在DNA修复机制中的作用,预计其他体细胞基因组改变会与这种异常相关。c-erbB-2(HER-2/neu)癌基因的扩增及相应p185erbB-2蛋白的过表达与乳腺癌的预后及对治疗的反应有关。在一项对62例福尔马林固定石蜡包埋的浸润性EOBC(诊断年龄在35岁及以下)的回顾性研究中,使用独特序列探针通过荧光原位杂交(FISH)检测到的c-erbB-2基因扩增状态,与通过免疫组织化学(IHC)测量的p53蛋白积累及表型特征进行了比较。p185erbB2蛋白表达也通过免疫组织化学进行检测,同时检测雌激素受体(ER)和孕激素受体(PR)表达。将33例淋巴结阴性EOBC病例的子集数据与70例36岁以上女性诊断出的淋巴结阴性肿瘤进行比较。与老年女性的淋巴结阴性乳腺癌相比,淋巴结阴性EOBC更有可能具有高级别、高增殖率、ER和/或PR阴性以及p53过表达(p<0.05)。EOBC中c-erbB-2扩增发生率更高的趋势(21%对9%)接近显著水平(p=0.07)。在EOBC中,与老年女性肿瘤中这些标志物的显著关联相反,c-erbB-2扩增和p53过表达与高肿瘤分级或高细胞增殖率无关。与老年女性发生的乳腺癌相比,包括c-erbB-2基因扩增和p53蛋白过表达在内的肿瘤标志物异常在EOBC女性中出现的速率不同。这一发现可能反映了EOBC的不同发病机制,值得进一步研究。